Related Experiment Video
Updated: Feb 13, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
Published on: January 17, 2025
Increased intracellular activity of MP1102 and NZ2114 against Staphylococcus aureus in vitro and in vivo
Xiao Wang1,2, Xiumin Wang3,4, Da Teng1,2
1Key Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing, 100081, P. R. China.
Abstract:
Treatment of Staphylococcus aureus infections remains very difficult due to its capacity to survive intracellularly and its multidrug resistance. In this study, the extracellular/intracellular activities of plectasin derivatives-MP1102/NZ2114 were investigated against three methicillin-susceptible/-resistant S. aureus (MSSA/MRSA) strains in RAW 264.7 macrophages and mice to overcome poor intracellular activity. Antibacterial activities decreased 4-16-fold under a mimic phagolysosomal environment. MP1102/NZ2114 were internalized into the cells via clathrin-mediated endocytosis and macropinocytosis and distributed in the cytoplasm; they regulated tumor necrosis factor-α, interleukin-1β and interleukin-10 levels. The extracellular maximal relative efficacy (Emax) values of MP1102/NZ2114 towards the three S. aureus strains were >5-log decrease in colony forming units (CFU). In the methicillin-resistant and virulent strains, MP1102/NZ2114 exhibited intracellular bacteriostatic efficacy with an Emax of 0.42-1.07-log CFU reduction. In the MSSA ATCC25923 mouse peritonitis model, 5 mg/kg MP1102/NZ2114 significantly reduced the bacterial load at 24 h, which was superior to vancomycin. In MRSA ATCC43300, their activity was similar to that of vancomycin. The high virulent CVCC546 strain displayed a relatively lower efficiency, with log CFU decreases of 2.88-2.91 (total), 3.41-3.50 (extracellular) and 2.11-2.51 (intracellular) compared with vancomycin (3.70). This suggests that MP1102/NZ2114 can be used as candidates for treating intracellular S. aureus.
Insights
Plectasin derivatives MP1102/NZ2114 show promise in treating intracellular Staphylococcus aureus infections, including multidrug-resistant strains. These compounds demonstrated significant efficacy in both cellular and mouse models, outperforming vancomycin in some cases.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Staphylococcus aureus infections are difficult to treat due to intracellular survival and multidrug resistance.
- Existing treatments face challenges in overcoming intracellular bacterial activity.
Purpose of the Study:
- To investigate the extracellular and intracellular activities of plectasin derivatives MP1102/NZ2114 against Staphylococcus aureus (MSSA/MRSA).
- To evaluate the efficacy of MP1102/NZ2114 in cellular and murine models of infection.
Main Methods:
- Assessed antibacterial activity in a simulated phagolysosomal environment.
- Investigated cellular uptake mechanisms (clathrin-mediated endocytosis, macropinocytosis).
- Evaluated efficacy in RAW 264.7 macrophages and mouse models (peritonitis).
- Measured cytokine regulation (TNF-α, IL-1β, IL-10).
Main Results:
- MP1102/NZ2114 exhibited potent extracellular activity (>5-log CFU reduction).
- Intracellular efficacy ranged from 0.42-1.07-log CFU reduction against resistant strains.
- In a mouse model, MP1102/NZ2114 outperformed vancomycin against MSSA and showed comparable efficacy against MRSA.
- Activity against a highly virulent strain was notable, though less than vancomycin.
Conclusions:
- Plectasin derivatives MP1102/NZ2114 demonstrate significant potential for treating intracellular Staphylococcus aureus infections.
- These compounds offer a promising therapeutic strategy against multidrug-resistant strains.
- Further development is warranted for MP1102/NZ2114 as anti-staphylococcal agents.
Related Concept Videos
Intracellular Signaling Cascades
Increasing Function
Equivalence: In Vitro and In Vivo Bioequivalence
Increased Body Temperature
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Primary Active Transport

